Hematopoietic stem cell transplantation was first reported for patients with systemic lupus erythematosus in 1997. The procedure has since been performed worldwide including in Europe, in Brazil, and in China. A National Institutes of Health-funded phase III clinical trial of hematopoietic stem cell transplantation for refractory systemic lupus erythematosus is anticipated to begin in 2003. Enc...

Objective(s): Cord blood (CB) is known as a valuable source of hematopoietic stem cells (HSC). Identifying strategies that enhance expansion and maintain engraftment and homing capacity of HSCs can improve transplant efficiency. In this study, we examined different culture conditions on ex vivo expansion and homing capacity of CB-HSCs. Materials and Methods: In this study, 4-5 different units o...

Background: One of the major changes in transplantation has been the development of multiple new sources of stem cells (bone marrow, peripheral blood stem cells, and cord blood) for transplant. Because of this proliferation, many now use the term stem cell transplantation (SCT) instead of bone marrow transplantation (BMT) to encompass these various types of transplantation. The aime of the pres...

More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell "rescue." Autologous HSCT is...

Hematopoiesis is sustained by a renewable pool of stem cells that interacts with distinct, sequential and specific microenvironments during normal development and throughout adult life. Hematopoietic stem cells (HSCs) are unique in their ability to migrate to various sites, ensuring the safety and integrity of their regenerative potential. This review is focused on the guidance cues and molecul...

541 01. Which of the following newly diagnosed patients is most likely to be considered for an allogeneic hematopoietic stem cell transplant (HSCT)? a. Mr. Williams, a 23-year-old with acute leukemia b. Mrs. Smith, a 45-year-old with breast cancer c. Mr. Henderson, a 54-year-old with multiple myeloma d. Ms. Elliott, a 36-year-old with Hodgkin lymphoma 02. Mrs. Johnston is being evaluated for HS...

The recognition that the immune system can play a major role in the control and cure of transplantable disorders led to the development of reduced-intensity allogeneic transplantation. The notion is that a compromise can be made between the intensity of conditioning and the fostering of graft-versus-host disease/ graft-versus-leukemia (GVHD/GVL), allowing the use of less intense conditioning wi...

CD4 regulatory T cells play a critical role in establishment of immune tolerance and prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. The recovery and maintenance of regulatory T cells is dependent on homeostatic factors including the generation of naïve regulatory T cells from hematopoietic precursor cells, the proliferation and expansion of mat...

The purpose of regenerative medicine [6], especially tissue engineering, is to replace damaged tissue with new tissue that will allow the body to resume normal function. The uniqueness of tissue engineering is that it can restore normal structure in addition to repairing tissue function, and is often accomplished using stem cells [7]. The first type of tissue engineering using stem cells [7] wa...